Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Tobii AB in connection with a directed share issue
Mandate

Vinge has advised Tobii AB (publ) in connection with a directed share issue

November 08, 2021 Capital Markets and Public M&A

Vinge has advised Tobii AB in connection with a directed share issue whereby the company receives approximately SEK 300 million in gross issue proceeds.

The share issue was carried out as an accelerated book building process and directed to selected Swedish and international institutional investors. Tobii intends to use the issue proceeds to finance the acquisition of Phasya, to finance the acquisition of Acapela Group and to strengthen the balance sheet in both Tobii and Tobii Dynavox in connection with the separate listing of Tobii Dynavox and thereby create headroom for further acquisitions and investments.

Vinge’s team has consisted of Jesper Schönbeck, Amanda Knutsson, Joel Magnusson and David Bokliden.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024